Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)

China · Delayed Price · Currency is CNY

7.42

+0.11 (1.50%)

Jul 31, 2026, 3:00 PM CST

-29.67% (1Y)

Market Cap	6.12B -29.9%
Revenue (ttm)	794.80M -0.8%
Net Income	108.03M -49.4%
EPS	0.13 -47.2%
Shares Out	825.10M
PE Ratio	55.26
Forward PE	n/a
Dividend	0.06 (0.86%)
Ex-Dividend Date	Jul 17, 2026

Volume	7,836,071
Open	7.32
Previous Close	7.31
Day's Range	7.30 - 7.46
52-Week Range	7.15 - 12.51
Beta	-0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About SHA:603229

Zhejiang Ausun Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical formulations, specialty active pharmaceutical ingredients (APIs), and pharmaceutical intermediates in China and internationally. The company offers products for liver diseases, respiratory system diseases, cardiovascular and cerebrovascular diseases, high-end fluorine products, prostaglandins, antibacterial agents, gout, anti-tumor treatments, and nervous system disorders. It also provides customi... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2010

Employees 1,328

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603229

Full Company Profile

Financial Performance

In 2025, SHA:603229's revenue was 792.76 million, a decrease of -0.32% compared to the previous year's 795.29 million. Earnings were 130.57 million, a decrease of -36.86%.

Financial Statements